Forest Licenses Novel Diabetes Compounds from TransTech Pharma
Debbie Tranter
Abstract
Forest Laboratories is paying up to USD 1.105 B to in-licence novel liver-selective Glucokinase Activators discovered by TransTech Pharma and currently in preclinical and Phase I stages.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.